9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

Estimated reading time: < 1 min

Condition: Ovarian

Estimated Enrollment: 12

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: To determine the immunologic response to the treatment with MKC1106-PP regimen and 2) to determine the safety and adverse event profile of MKC1106-PP,  to determine the blood plasmid levels by PCR analysis,  measure cytokine levels, to describe any objective tumor responses to the treatment with MKC1106-PP

Interventions: PSMA/PRAME, PSMA/PRAME

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: September 2009

Completion Date: November 2009

Last  Posted Date: August 3, 2010

Location: Arizona Cancer Center, Tuscon, Arizona, United States

Website Link: https://ClinicalTrials.gov/show/NCT00423254

Was this article helpful?
Dislike 0